Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Recordati has signed an exclusive license agreement with a subsidiary of Watson Pharmaceuticals, for the marketing and sale in 29 European countries of Kentera, a bi-weekly oxybutynin transdermal patch indicated for the symptomatic treatment of urge incontinence.
Subscribe to our email newsletter
Kentera was approved through the centralized procedure by the EMEA in 2004 and has been on the market in a number of countries with current sales of over E7 million.
Giovanni Recordati, chairman and CEO of Recordati, said: “The acquisition of Kentera, an original system for the administration of a well-known drug improving its tolerability profile, reinforces Recordati’s focus in the urology area where it is developing silodosin, indicated for the treatment of benign prostate hypertrophy, due for filing in Europe in the second half of 2008.”